Xortx Therapeutics Inc Financials
This page shows Xortx Therapeutics Inc (XRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Xortx Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Xortx Therapeutics Inc generates a -16.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
For every $1 of reported earnings, Xortx Therapeutics Inc generates $1.04 in operating cash flow (-$2.8M OCF vs -$2.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Xortx Therapeutics Inc reported -$2.7M in net income in fiscal year 2025.
Cash & Balance Sheet
Xortx Therapeutics Inc generated -$2.8M in free cash flow in fiscal year 2025, representing cash available after capex.
Xortx Therapeutics Inc held $865K in cash against $0 in long-term debt as of fiscal year 2025.
Xortx Therapeutics Inc had 7M shares outstanding in fiscal year 2025.
Margins & Returns
Xortx Therapeutics Inc's ROE was -16.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Xortx Therapeutics Inc invested $4K in capex in fiscal year 2025, funding long-term assets and infrastructure.
XRTX Income Statement
XRTX Balance Sheet
XRTX Cash Flow Statement
XRTX Financial Ratios
Similar Companies
Frequently Asked Questions
Is Xortx Therapeutics Inc profitable?
No, Xortx Therapeutics Inc (XRTX) reported a net income of -$2.7M in fiscal year 2025.
What is Xortx Therapeutics Inc's return on equity (ROE)?
Xortx Therapeutics Inc (XRTX) has a return on equity of -16.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Xortx Therapeutics Inc's free cash flow?
Xortx Therapeutics Inc (XRTX) generated -$2.8M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Xortx Therapeutics Inc's operating cash flow?
Xortx Therapeutics Inc (XRTX) generated -$2.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Xortx Therapeutics Inc's total assets?
Xortx Therapeutics Inc (XRTX) had $2.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Xortx Therapeutics Inc's capital expenditures?
Xortx Therapeutics Inc (XRTX) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Xortx Therapeutics Inc's debt-to-equity ratio?
Xortx Therapeutics Inc (XRTX) had a debt-to-equity ratio of -0.84 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xortx Therapeutics Inc's return on assets (ROA)?
Xortx Therapeutics Inc (XRTX) had a return on assets of -99.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Xortx Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Xortx Therapeutics Inc (XRTX) had $865K in cash against an annual operating cash burn of $2.8M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Xortx Therapeutics Inc's earnings high quality?
Xortx Therapeutics Inc (XRTX) has an earnings quality ratio of 1.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Xortx Therapeutics Inc?
Xortx Therapeutics Inc (XRTX) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.